L'Europe refuse le traitement Leqembi contre Alzheimer, un coup dur pour les patients et leurs proches. 😔
Coup de tonnerre : l’Europe refuse le traitement contre Alzheimer que tout le monde attendait
l.futura-sciences.com
November 12, 2025 at 7:29 AM
L'Europe refuse le traitement Leqembi contre Alzheimer, un coup dur pour les patients et leurs proches. 😔
Both academic detractors who posted criticisms of the study online received consulting & research fees from drugmakers.
More shocking was the response from federal regulators tasked with ensuring drugs like Aduhelm & Leqembi are safe.
More shocking was the response from federal regulators tasked with ensuring drugs like Aduhelm & Leqembi are safe.
Science for Sale: How FDA Is Captured
There were obvious reasons why some people would want to silence Espay. New Alzheimer’s drugs projected to reach $17B by 2033.
Anything jeopardizing those sales posed threat to pharmaceutical companies & their stakeholders.
www.levernews.com/science-for-...
There were obvious reasons why some people would want to silence Espay. New Alzheimer’s drugs projected to reach $17B by 2033.
Anything jeopardizing those sales posed threat to pharmaceutical companies & their stakeholders.
www.levernews.com/science-for-...
Science For Sale: How Drugmakers Captured The FDA
The pharmaceutical industry spent decades manipulating the country’s top drug regulator into rubber-stamping its products. The Trump administration is making matters worse.
www.levernews.com
November 11, 2025 at 1:53 AM
Both academic detractors who posted criticisms of the study online received consulting & research fees from drugmakers.
More shocking was the response from federal regulators tasked with ensuring drugs like Aduhelm & Leqembi are safe.
More shocking was the response from federal regulators tasked with ensuring drugs like Aduhelm & Leqembi are safe.
Science For Sale: How Drugmakers Captured The FDA www.levernews.com/science-for-... Last Oct the neurology professor his colleagues posted the results of their study online, writing that patients taking Aduhelm & Leqembi were 2 to nearly 3 Xs as likely to die as those treated in the clinical trials
Science For Sale: How Drugmakers Captured The FDA
The pharmaceutical industry spent decades manipulating the country’s top drug regulator into rubber-stamping its products. The Trump administration is making matters worse.
www.levernews.com
November 8, 2025 at 1:45 PM
Science For Sale: How Drugmakers Captured The FDA www.levernews.com/science-for-... Last Oct the neurology professor his colleagues posted the results of their study online, writing that patients taking Aduhelm & Leqembi were 2 to nearly 3 Xs as likely to die as those treated in the clinical trials
Signal or noise? > Eisai plots label expansion for subcutaneous Leqembi,
details early launch progress >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical
details early launch progress >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical
Eisai plots label expansion for subcutaneous Leqembi,
details early launch progress
Eisai said it’s planning a rolling FDA submission next month to expand the use of its Biogen-partnered subcutaneous Alzheimer’s treatment, the latest effort to stoke the companies’ rivalry with Eli Lilly. Leqembi was first approved ...
dlvr.it
November 6, 2025 at 8:33 PM
Signal or noise? > Eisai plots label expansion for subcutaneous Leqembi,
details early launch progress >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical
details early launch progress >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical
Updates for Lecanemab (Leqembi) for Alzheimer's Disease
Read for free: bit.ly/495YIxD
#AlzheimersDisease #FOAMed
Read for free: bit.ly/495YIxD
#AlzheimersDisease #FOAMed
November 6, 2025 at 5:04 PM
Updates for Lecanemab (Leqembi) for Alzheimer's Disease
Read for free: bit.ly/495YIxD
#AlzheimersDisease #FOAMed
Read for free: bit.ly/495YIxD
#AlzheimersDisease #FOAMed
Bruising is a specifically listed potential side effect for the subcutaneous (under the skin) injection form of lecanemab (Leqembi Iqlik), an FDA-approved monoclonal antibody treatment for early-stage Alzheimer's disease.
November 6, 2025 at 2:33 PM
Bruising is a specifically listed potential side effect for the subcutaneous (under the skin) injection form of lecanemab (Leqembi Iqlik), an FDA-approved monoclonal antibody treatment for early-stage Alzheimer's disease.
Leqembi is an Alzheimer’s drug that requires an MRI. Somebody needs to ask if Trump is taking Leqembi.
November 6, 2025 at 11:59 AM
Leqembi is an Alzheimer’s drug that requires an MRI. Somebody needs to ask if Trump is taking Leqembi.
I wrote about the approval of Leqembi for Alzheimer's in Canada for Being Patient.
Compared to other countries, there's less transparency with the approval process. It took more than 2 years for regulators to decide.
beingpatient.com/alzheimers-d...
Compared to other countries, there's less transparency with the approval process. It took more than 2 years for regulators to decide.
beingpatient.com/alzheimers-d...
Alzheimer's Drug Leqembi Approved in Canada
Alzheimer’s drug Leqembi will soon be available in Canada, but it isn’t clear whether it will be covered by public health insurance.
beingpatient.com
November 6, 2025 at 1:13 AM
I wrote about the approval of Leqembi for Alzheimer's in Canada for Being Patient.
Compared to other countries, there's less transparency with the approval process. It took more than 2 years for regulators to decide.
beingpatient.com/alzheimers-d...
Compared to other countries, there's less transparency with the approval process. It took more than 2 years for regulators to decide.
beingpatient.com/alzheimers-d...
Erst seit wenigen Wochen ist das Lecanemab-haltige #Alzheimer Medikament Leqembi® von Biogen auf dem deutschen Markt, da bekommt es schon Konkurrenz. #Donanemab (Kisunla®, Lilly Pharma) hat das identische Anwendungsgebiet.
Kisunla: Neues Alzheimer-Medikament in Deutschland verfügbar
Erst seit wenigen Wochen ist das Lecanemab-haltige Alzheimer-Medikament Leqembi® von Biogen auf dem deutschen Markt, da bekommt es schon Konkurrenz. Do...
www.pharmazeutische-zeitung.de
November 3, 2025 at 4:22 PM
Erst seit wenigen Wochen ist das Lecanemab-haltige #Alzheimer Medikament Leqembi® von Biogen auf dem deutschen Markt, da bekommt es schon Konkurrenz. #Donanemab (Kisunla®, Lilly Pharma) hat das identische Anwendungsgebiet.
I'm gonna go all in that Trump is on Leqembi.
Hence the MRIs.
Hence the MRIs.
The FDA Now Requires Increased MRI Monitoring for Alzheimer’s Patients Who Are Treated with Leqembi – Patient Worthy
patientworthy.com
October 30, 2025 at 9:36 PM
I'm gonna go all in that Trump is on Leqembi.
Hence the MRIs.
Hence the MRIs.
Health Canada announced approval for lecanemab, commercially known as “Leqembi.” The treatment has already been approved in some other countries, including the US, the UK, Japan, Mexico and China, and is under regulatory review in 15 other countries and regions, including the European Union.
‘This is a big deal’: Health Canada approves 1st drug to slow Alzheimer’s disease - National | Globalnews.ca
The treatment, lecanemab, has already been approved in some other countries, including the U.S., the U.K., Japan, Mexico and China.
globalnews.ca
October 30, 2025 at 4:12 PM
Health Canada announced approval for lecanemab, commercially known as “Leqembi.” The treatment has already been approved in some other countries, including the US, the UK, Japan, Mexico and China, and is under regulatory review in 15 other countries and regions, including the European Union.
Leqembi® Records Impressive Sales Growth of 18 Billion Yen in Q3 2025#Sweden#Stockholm#Eisai#Leqembi#BioArctic
Leqembi® Records Impressive Sales Growth of 18 Billion Yen in Q3 2025
Leqembi® has achieved a remarkable sales milestone, totaling 18 billion yen in the third quarter of 2025, marking a significant growth for the treatment of Alzheimer's disease.
third-news.com
October 30, 2025 at 10:47 AM
Leqembi® Records Impressive Sales Growth of 18 Billion Yen in Q3 2025#Sweden#Stockholm#Eisai#Leqembi#BioArctic
Leqembi® Sees Impressive Revenue of 18 Billion Yen in Q3 2025#Sweden#Stockholm#Eisai#Leqembi#BioArctic
Leqembi® Sees Impressive Revenue of 18 Billion Yen in Q3 2025
BioArctic and Eisai revealed Leqembi's remarkable sales in Q3 2025, totaling 18 billion yen, showcasing continued growth in Alzheimer's treatment.
third-news.com
October 30, 2025 at 10:44 AM
Leqembi® Sees Impressive Revenue of 18 Billion Yen in Q3 2025#Sweden#Stockholm#Eisai#Leqembi#BioArctic
Ja, das wäre wirklich interessant zu wissen @swissmedic.bsky.social. Vor allem weil Leqembi ja ausschliesslich in Solothurn für den Weltmarkt produziert wird.
October 30, 2025 at 7:06 AM
Ja, das wäre wirklich interessant zu wissen @swissmedic.bsky.social. Vor allem weil Leqembi ja ausschliesslich in Solothurn für den Weltmarkt produziert wird.
Health Canada has authorized LEQEMBI® (lecanemab) for the treatment of early Alzheimer’s disease. Lecanemab serves as a comparative control in #TRIDENT’s preclinical validation studies.
globalnews-ca.cdn.ampproject.org/c/s/globalne...
globalnews-ca.cdn.ampproject.org/c/s/globalne...
Health Matters: New drug slows down Alzheimer’s decline | Watch News Videos Online
globalnews-ca.cdn.ampproject.org
October 29, 2025 at 10:29 PM
Health Canada has authorized LEQEMBI® (lecanemab) for the treatment of early Alzheimer’s disease. Lecanemab serves as a comparative control in #TRIDENT’s preclinical validation studies.
globalnews-ca.cdn.ampproject.org/c/s/globalne...
globalnews-ca.cdn.ampproject.org/c/s/globalne...
Health Canada has announced approval for lecanemab, commercially known as "Leqembi."
globalnews.ca/news/1150036...
globalnews.ca/news/1150036...
‘This is a big deal’: Health Canada approves 1st drug to slow Alzheimer’s disease - National | Globalnews.ca
The treatment, lecanemab, has already been approved in some other countries, including the U.S., the U.K., Japan, Mexico and China.
globalnews.ca
October 29, 2025 at 6:07 PM
Health Canada has announced approval for lecanemab, commercially known as "Leqembi."
globalnews.ca/news/1150036...
globalnews.ca/news/1150036...
Leqembi medication was the medication named.
October 29, 2025 at 3:10 AM
Leqembi medication was the medication named.
This time it's his left. Are they switch-hitting IVs for Kisunla (donanemab) and Leqembi (lecanemab)?
October 29, 2025 at 1:48 AM
This time it's his left. Are they switch-hitting IVs for Kisunla (donanemab) and Leqembi (lecanemab)?
This pharmacist has a theory - both Leqembi and Kisunla, 2 drugs given by infusion to treat Alzheimer’s dementia require monitoring with periodic MRIs to assess for safety.
October 29, 2025 at 1:07 AM
This pharmacist has a theory - both Leqembi and Kisunla, 2 drugs given by infusion to treat Alzheimer’s dementia require monitoring with periodic MRIs to assess for safety.
I take that back, he could be on Leqembi for Alzheimer’s. They have to monitor for hemorrhages on that drug
October 28, 2025 at 11:40 PM
I take that back, he could be on Leqembi for Alzheimer’s. They have to monitor for hemorrhages on that drug
There is a drug called Leqembi which is used for Alzheimer's disease. It requires enhanced imaging (read MRI) to surveil for ARIA-E and ARIA-H......
October 28, 2025 at 8:50 PM
There is a drug called Leqembi which is used for Alzheimer's disease. It requires enhanced imaging (read MRI) to surveil for ARIA-E and ARIA-H......
Probably mixing bleach with the Leqembi.
October 28, 2025 at 8:42 PM
Probably mixing bleach with the Leqembi.
He's obviously on Lecanemab (Leqembi), they are doing the MRI to check for brain bleeds.
October 28, 2025 at 8:23 PM
He's obviously on Lecanemab (Leqembi), they are doing the MRI to check for brain bleeds.
🧠 New infographic: FDA-approved Alzheimer's treatments at a glance—how they work, administration methods, and which disease stages they target.
View it here: https://bit.ly/42Ziuaq
Made possible by sponsorships from Eisai and Lilly.
View it here: https://bit.ly/42Ziuaq
Made possible by sponsorships from Eisai and Lilly.
October 28, 2025 at 8:01 PM
🧠 New infographic: FDA-approved Alzheimer's treatments at a glance—how they work, administration methods, and which disease stages they target.
View it here: https://bit.ly/42Ziuaq
Made possible by sponsorships from Eisai and Lilly.
View it here: https://bit.ly/42Ziuaq
Made possible by sponsorships from Eisai and Lilly.
加拿大卫生部已批准一种被证实能减缓阿尔茨海默病进程的药物。
这款名为仑卡奈单抗（商品名为Leqembi）的药物，是加拿大首个获批、能针对大脑中β-淀粉样蛋白斑块堆积的治疗药物。一般认为这种斑块的形成是阿尔茨海默病的可能病因之一。
这种药物是一种实验室合成的抗体，可与淀粉样蛋白结合，帮助中和并清除它们。仑卡奈单抗必须在痴呆早期、患者出现轻度认知障碍时使用。
仑卡奈单抗是一种治疗药物，而非治愈药，必须每两周静脉注射一次，并需要MRI扫描监测副作用。
这款名为仑卡奈单抗（商品名为Leqembi）的药物，是加拿大首个获批、能针对大脑中β-淀粉样蛋白斑块堆积的治疗药物。一般认为这种斑块的形成是阿尔茨海默病的可能病因之一。
这种药物是一种实验室合成的抗体，可与淀粉样蛋白结合，帮助中和并清除它们。仑卡奈单抗必须在痴呆早期、患者出现轻度认知障碍时使用。
仑卡奈单抗是一种治疗药物，而非治愈药，必须每两周静脉注射一次，并需要MRI扫描监测副作用。
October 28, 2025 at 5:49 PM
加拿大卫生部已批准一种被证实能减缓阿尔茨海默病进程的药物。
这款名为仑卡奈单抗（商品名为Leqembi）的药物，是加拿大首个获批、能针对大脑中β-淀粉样蛋白斑块堆积的治疗药物。一般认为这种斑块的形成是阿尔茨海默病的可能病因之一。
这种药物是一种实验室合成的抗体，可与淀粉样蛋白结合，帮助中和并清除它们。仑卡奈单抗必须在痴呆早期、患者出现轻度认知障碍时使用。
仑卡奈单抗是一种治疗药物，而非治愈药，必须每两周静脉注射一次，并需要MRI扫描监测副作用。
这款名为仑卡奈单抗（商品名为Leqembi）的药物，是加拿大首个获批、能针对大脑中β-淀粉样蛋白斑块堆积的治疗药物。一般认为这种斑块的形成是阿尔茨海默病的可能病因之一。
这种药物是一种实验室合成的抗体，可与淀粉样蛋白结合，帮助中和并清除它们。仑卡奈单抗必须在痴呆早期、患者出现轻度认知障碍时使用。
仑卡奈单抗是一种治疗药物，而非治愈药，必须每两周静脉注射一次，并需要MRI扫描监测副作用。